Skip to content

OS Therapies OSTX Quick ratio

Quick ratio at other companies

Immunome logo
ImmunomeIMNM
21.7×+11.2×
CTO
Citius Oncology, Inc.CTOR
0.1×+0.1×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
7.7×-14.9×
Arcus Biosciences logo
Arcus BiosciencesRCUS
-1.3×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
6.4×+4.3×
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
11.4×-7.6×

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Calculated from OS Therapies’s reported figures.

Based on the most recent quarter.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's quick ratio?
OS Therapies (OSTX) reported quick ratio of 0.1× in Q1 2026.
How has OS Therapies's quick ratio changed year-over-year?
OS Therapies's quick ratio decreased by 95.3% year-over-year, from 1.2× to 0.1×.
What is the long-term trend for OS Therapies's quick ratio?
Over 2 years (2023 to 2025), OS Therapies's quick ratio has grown at a -6.0% compound annual growth rate (CAGR), from 0× to 0×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.